Menu
Search
|

Menu

Close
X

Adaptimmune Therapeutics PLC ADAP.OQ (NASDAQ Stock Exchange Global Select Market)

3.84 USD
-- (--)
As of Mar 19
chart
Previous Close 3.84
Open --
Volume --
3m Avg Volume 111,446
Today’s High --
Today’s Low --
52 Week High 14.62
52 Week Low 3.60
Shares Outstanding (mil) 93.52
Market Capitalization (mil) 763.12
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.11 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
60
FY17
38
FY16
14
EPS (USD)
FY18
-0.164
FY17
-0.137
FY16
-0.169
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
44.03
8.39
Price to Book (MRQ)
vs sector
3.33
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.02
LT Debt to Equity (MRQ)
vs sector
0.00
11.35
Return on Investment (TTM)
vs sector
-32.06
13.82
Return on Equity (TTM)
vs sector
-35.60
15.25

EXECUTIVE LEADERSHIP

David Mott
Non-Executive Chairman of the Board, Since 2017
Salary: --
Bonus: --
James Noble
Chief Executive Officer, Director, Since 2014
Salary: --
Bonus: --
Adrian Rawcliffe
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
William Bertrand
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Sebastien Desprez
Vice President - Communications and Investor Relations, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60 Jubilee Avenue
ABINGDON     OX14 4RX

Phone: +441235.430000

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

SPONSORED STORIES